OBI Pharma Valuation
Is 4174 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 4174 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 4174's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 4174's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4174?
Key metric: As 4174 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is 4174's PB Ratio? | |
|---|---|
| PB Ratio | 6.1x |
| Book | NT$2.36b |
| Market Cap | NT$14.44b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 209.6x |
| Enterprise Value/EBITDA | -7.3x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does 4174's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 7.2x | ||
6712 Ever Supreme Bio Technology | 9x | n/a | NT$14.2b |
4728 Sunmax Biotechnology | 11.1x | n/a | NT$15.1b |
4147 TaiMed Biologics | 5.3x | -0.07% | NT$21.8b |
4162 PharmaEngine | 3.4x | -26.3% | NT$13.5b |
4174 OBI Pharma | 6.1x | n/a | NT$14.4b |
Price-To-Book vs Peers: 4174 is good value based on its Price-To-Book Ratio (6.1x) compared to the peer average (7.2x).
Price to Book Ratio vs Industry
How does 4174's PB Ratio compare vs other companies in the TW Biotechs Industry?
| 0 Companies | Price / Book | Estimated Growth | Market Cap |
|---|
| 0 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Book vs Industry: 4174 is expensive based on its Price-To-Book Ratio (6.1x) compared to the TW Biotechs industry average (3.9x).
Price to Book Ratio vs Fair Ratio
What is 4174's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 6.1x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate 4174's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
YungShin Global Holding
NT$15.4b
Through its subsidiaries, invests in, manufactures, and sells medicines, animal drugs, agricultural chemicals, industrial medicines, and cosmetics in Taiwan, Mainland China, Japan, and the United States.
3705
NT$57.90
7D
8.2%
1Y
27.1%
Winston Medical Supply
NT$1.6b
Winston Medical Supply Co.,Ltd. develops, manufactures, and distributes pharmaceuticals, nutrition supplements, and cosmeceutical products.
6817
NT$88.30
7D
-1.6%
1Y
-13.4%
RBC Bioscience
NT$254.3m
Researches, develops, manufactures, and sells reagents and devices for life science and molecular diagnosis in Europe, the United States, Asia, Taiwan, Africa, and Australia.
6848
NT$19.60
7D
-0.5%
1Y
29.8%